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Objective: Our aim was to compare the efficacy of surgical versus percutaneous administration of skeletal myoblasts (SkM) in a swine model
of chronic myocardial infarction and to determine the mechanism(s) involved in their beneficial effect.
Methods: Two months after induction of myocardial infarction (MI), Goettingen miniature pigs underwent autologous SkM transplant either
by direct surgical injection (n=6) or percutaneous access and intramyocardial delivery under fluoroscopic and echocardiographic guidance
(n=6). Control animals received media alone (n=4). Functional analysis was performed by 2D echocardiography. Myoblast engraftment, in
vivo cell differentiation, vessel formation, fibrosis, and the ratio between collagen type I/III deposition were analyzed in the infarct (IA) and
non-infarct area (NIA) by immunohistochemistry.
Results: Animals received a median of 407.55±115x106 BrdU-labeled autologous SkM. Myoblast transplant was associated with a
statistically significant increase in left ventricular ejection fraction (p<0.01), increased vasculogenesis and decreased fibrosis (p<0.05), and
reduced collagen type I/III ratio in the IA and NIA areas as compared with control animals. No differences were found between groups
receiving SkM by percutaneous or surgical access.
Conclusions: Our results indicate that increased vasculogenesis and changes in matrix remodeling with decreased fibrosis are associated with
the beneficial effect of SkM transplant in chronic MI. The equivalent benefit observed from surgical and percutaneous delivery has important
clinical implications.
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 1. Introduction
Myocardial infarction (MI) is associated with loss and
dysfunction of cardiomyocytes that leads to heart failure and
death. The inability of resident cardiac stem cells to
contribute significantly to repair lost cardiomyocytes has
prompted the search for other sources of stem cells with the
potential to differentiate into cardiac muscle (reviewed in
[1]). The widest experience in cell therapy for cardiac
regeneration has been obtained with SkM [2]. Studies in
small [3–5] and large animal models [6,7] of myocardial
infarction over the last 10 years have indicated that SkM
engraft into the myocardium and differentiate into myotubes,
contributing to the improvement in cardiac function. These
preclinical studies have led to the development of the first
clinical trials in patients with cardiac failure, which have
further supported the suggestion that autologous myoblast
transplantation in patients with chronic MI has a potential
beneficial effect [8–11].
While most studies have used the surgical approach for
transplantation of myoblast in association with CABG
surgery [8,10,12], a recent report has demonstrated that
SkM can be safely administered using a percutaneous access
system with guided electromechanical catheter [11]. This
approach allows better assessment of the effect derived from
SkM transplant and also prevents the need for major surgery.
However, it is unclear whether surgical and percutaneous
delivery result in similar benefits in large animal models of
MI and thus have the same potential for human application.
It is generally accepted that SkM have a very limited
capacity, if any, to acquire characteristics of cardiac muscle
[13–15], and the mechanism by which they contribute to
cardiac function is currently unknown. Several studies have
suggested that the release of cytokines [16] or immune
mediated mechanisms [17] may be contributing factors.
Furthermore, the significant degree of cell attrition observed
after SkM transplant with less than 5% of the cells remaining
one week after transplant suggests that a direct benefit
derived from the cells is not the most likely explanation [18].
In our study we sought to understand the mechanism(s)
involved in the improvement in cardiac function observed
after SkM transplant, by examining their role in the process
of vasculogenesis and fibrosis that occurs after MI. From a
clinical perspective we analyzed whether percutaneous and
surgical delivery of SkM is associated with a similar benefit
in cardiac function.
2. Materials and methods
2.1. Animal preparation
In this study, adult Goettingen pigs (weighed 35–50 kg)
procured from our breeding center were maintained in the
animal facilities of CIFA (GLP accredited center at the
University of Navarra, Spain) in accordance with the Guide
for the Care and Use of Laboratory Animals published byUS National Institutes of Health (NIH Publication No. 85–
23, revised 1996) [19]. In each procedure, animals were pre-
medicated with atropine i.m. (0.05 mg/kg) and a combina-
tion of ketamine (10 mg/kg) and azaperon (2 mg/kg). After
sedation, animals received 3 mg/kg of etomidate i.v. and
were endotracheally intubated and mechanically ventilated
with supplementary oxygen. During surgery, anesthesia was
maintained with a combination of isofluorane and fentanyl
(0.01 mg/kg/h i.v.). At the end of the procedure, after
extubation, all animals received the non-steroidal analgesic
ketoprofen (3 mg/kg/24 h i.m.) for 3 days as well as
antibiotics (amoxicillin 7 mg/kg/24 h) for 5 days.
2.2. Myocardial infarction
All the pigs received a single dose of Heparin (1.5 mg/kg)
before the procedure commenced. Then an introducer sheath
was placed in the left carotid artery. Under fluoroscopic
guidance, a guiding catheter was positioned in the left
coronary ostium and myocardial infarction was induced by
selectively delivering (via a microcatheter advanced through
the guiding catheter) a vascular embolization coil (3- and 4-
mm Vortx coils, Boston Scientific/Target, Natick, MA, USA)
to the intermediate branch of first or second marginal artery.
Coronary occlusion occurred between 15 and 20 min after
coil placement, as demonstrated by coronary angiography
and ECG ST-segment changes. Following artery occlusion,
the delivery catheter was removed, the carotid artery ligated,
and the cut down site was closed with sutures.
2.3. Autologous myoblast transplantation
Eight weeks after the infarct, animals underwent
transplantation of autologous myoblasts either by direct
surgical intramyocardial injection with an ophthalmologic
needle (Steriseal Ophthalmic cannula 23G, Maersk Medical
Ltd. Redditch, B98 9NL GB) through a left intercostal
incision (n=6), or by percutaneous access through the
femoral artery (n=6) and intramyocardial delivery of
multiple injections under simultaneous fluoroscopic and
echocardiographic guidance using the Myocath® (Bioheart,
Florida) injection catheter. A total of 11(9–12) injections of
0.25–0.5 mL was performed in each animal in and around
the infarct area. Control animals received culture media
without cells either by percutaneous access (n=2) or surgical
delivery (n=2) with the same volume and number of
injections.
2.4. Cell culture and labeling
Muscle biopsies from pigs were obtained from one leg of
anesthetized animals and cut into small pieces (5–10 g)
under strictly sterile conditions in the operating room.
Muscle biopsy was stripped of connective tissue, minced and
digested as previously described [10]. Cells were grown in
79% Ham-F12 medium (GIBCO-BRL) supplemented with
746 J.J. Gavira et al. / Cardiovascular Research 71 (2006) 744–753
 at U
niversidad de N
avarra on M
ay 30, 2012
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 20% fetal calf serum, 10 ng/mL bFGF (SIGMA) and 1%
penicillin/streptomycin (GIBCO-BRL). Seventy two hours
before implantation, cells were labeled with 5 μg/mL BrdU.
Assessment of myoblast content was performed as described
[10]. At the time of harvest, cells were thoroughly washed to
eliminate any source of fetal calf serum and re-suspended in
medium at a concentration of 50–80×106 cells/mL.
2.5. Assessment of ventricular function and arrhythmias
Under general anesthesia, animals were placed in the left
lateral decubitus position and transthoracic two-dimensional
echocardiography was performed using a Sonos 4500
ultrasound system (Philips) and a 3 MHz linear array
transducer. Left ventricular remodeling was assessed by
measuring end systolic and diastolic volumes and diameters,
according to the American Society of Echocardiology. Left
ventricular ejection fraction (LVEF) was determined accord-
ing to Teichholz [20] in parasternal short axes. Echocardio-
graphic studies were performed at baseline (before infarct),
immediately before myoblast implantation and before
sacrifice. All studies were performed by the same investi-
gator blinded to the type of treatment. Measurements were
made in three cycles and the mean value was obtained. All
echocardiographic data were recorded at a similar heart rate.
Reproducibility values within studies were 2.8±6.4 mL (CV
5.5%) for LV end-diastolic volume and 0.3±4.6 (CV 6.6%)
for LVEF.
Animals underwent implantation of a Reveal Plus
Implantable loop recorder (Medtronic, Minneapolis, MN)
in the left chest region after myocardial infarction. Pre-
implantation mapping was performed in the left upper
parasternal region to optimize device sensing of R waves and
minimize T wave amplitude. Whenever possible, p wave
amplitude was optimized when an R/T ratio>3 could be
obtained. The implantable loop recorder is a continuous
electrocardiogram (ECG) monitor capable of recording
42 min of a single-lead ECG in compressed memory
mode. For the purpose of this study, the memory was
configured with 13 1-minute automatic activation bins. The
gain and sensitivity of the device were assessed after
implantation in the left and right lateral decubitus position
to optimize automatic detection. The parameters for auto-
matic detection were set to store events during a pause>3 s
and a heart rate<40 or >160 beats/min. After device
implantation, animals were seen for implantable loop
recorder interrogation with a standard pacemaker program-
mer (Medtronic 9790C) at 1, 2, 4 and 8 weeks after infarction
and at 1, 2, 4, 8 and 12 weeks after cells or media
implantation.
2.6. Histological and immunohistochemistry analysis
At the end of the experimental protocol (3 months after
myoblast implantation), animals were anesthetized with
ketamine and euthanized with pentobarbital and a saturatedsolution of potassium chloride, and the heart excised.
Explanted hearts were fixed in formalin for histological
analysis. Locations of myocardial infarction were visually
assessed. Tissue samples consisted of scar surrounded by a
ring of viable myocardium. Formalin-fixed tissues were
embedded in paraffin, and sections stained with hematox-
ylin–eosin and Gallego's trichrome method for qualitative
assessment. Paraffin-embedded blocks were cut in 5-μm
sections, deparaffinized and stained with the appropriate
antibodies. The detection of transplanted cells was primarily
based on the morphological analysis, the presence of BrdU
positive signals and the presence of cells positive for fast
myosin-heavy chain. Antibodies directed against fast
myosin-heavy chain (MY-32 clone, Zymed), BrdU (BrdU-
Dnase kit, Amersham), smooth muscle actin (DakoCytoma-
tion) and CD45 (Serotec) were used. MY-32 and CD45 were
followed by EnVision System Labelled Polymer Horse
Radish Peroxidase (DakoCytomation) and diaminobenzidine
(DakoCytomation) as a chromogen. Slides were counter-
stained with Harris hematoxylin (Sigma). For smooth muscle
actin EnVision System Labelled Polymer AP (DakoCytoma-
tion) was used, developed with new fucsin (Merck) and
counterstained with methyl green. BS-I lectin (Vector) was
used for staining of endothelial cells.
Vasculogenesis was evaluated in paraffin-embedded
sections by counting the size of areas occupied by smooth
muscle coated vessels in the infarct myocardium using
smooth muscle actin antibodies for immunostaining. Vas-
cular density was expressed as the area occupied by smooth
muscle coated blood vessels per high power field (15
sections were examined per heart). Images were processed
by Nikon Eclipse E800 microscope.
Sirius red staining was used to identify interstitial
collagen on slides as described previously [21]. Paraffin
sections (5 μm) were stained with Sirius Red F3B, which
specifically stains all types of fibrillar collagen. The sections
were rehydrated and then stained for 90 min in 0.1% Sirius
Red in saturated aqueous picric acid. Sections were then
treated with absolute alcohol for one minute, dehydrated, and
mounted. Sirius red staining was measured with an
interactive computerized image analysis system (Optimas
5.2 color image analysis). A density slice of the sirius red
positive staining area was produced and expressed as a
percentage of the area of the field occupied by collagen
(collagen volume fraction — CVF), and the mean of 15
fields captured with ×20 objective was calculated. Analysis
of collagen type I and III was performed using a polarized
filter on sections stained for collagen with Sirius Red.
Collagen type I is characterized by a red/yellow and type III
by green collagen fibrils [22]. The percentage of the infarcted
area stained for collagen type I and III was calculated in 15
randomly selected fields captured with ×20 objective. The
CVF and collagen type I/III ratio was analyzed separately in
the infarct (IA) and non-infarct (NIA) area. NIA was
considered to be the area with normal cardiomyocytes
surrounding the scar tissue.
Fig. 1. Rhythm strip obtained with an implantable loop recorder during a non-sustained ventricular tachycardia 24 h after myoblast transplantation.
Table 2
Echocardiographic analysis in the different groups of animals
Baseline Pretransplant 3 months p-value
LVEF
Percutaneous 70.3 (5.7) 47.5 (8.7) 63.00 (8.1) 0.008
Surgical 74.2 (3.7) 49.0 (8.1) 64.4 (7.5) 0.009
Control 72.5 (6.8) 50.2 (10.4) 49.5 (9.1) 0.995
LVEDD
Percutaneous 35 (3.1) 36.4 (2.1) 38.3 (5.7) 0.576
Surgical 33.3 (1.5) 37.7 (5.1) 33.2 (2.2) 0.325
Control 31.3 (5.1) 30.3 (11.4) 38.3 (6.1) 0.080
LVESD
Percutaneous 20.7 (0.9) 27.6 (2.3) 25.6 (6.4) 0.652
Surgical 17.5 (1.6) 25.1 (3.7) 19.9 (2.6) 0.257
Control 19.2 (3.3) 26.6 (4.2) 27.8 (8.2) 0.302
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 2.7. Statistical analysis
Statistical analysis was performed with the SPSS 12.0 for
windows software package. Comparisons were performed
using the paired and unpaired t test when appropriate, once
normality had been demonstrated using the Shapiro–Wilk
and Kolmogorov–Smirnov normality test. In cases of non-
normal distribution, the Wilcoxon test was used. Compar-
isons for repeated measurements were performed with
ANOVA or the Friedman test. Lineal regression analysis
was performed using Pearson correlation coefficients.
Descriptive analysis is presented as mean (SEM) for
quantitative variables or median (IQR) for categorical
variables. Statistical significance was achieved if p values
were <0.05.
3. Results
Myocardial infarction was created in 19 pigs by
intracoronary insertion of a coil; 3 animals were excluded
because of lethal ventricular fibrillation at the time of the
infarct. Thus the study group included 16 animals which
were divided into groups including 4 control animals and 12
treated with myoblasts (6 by direct surgical injection and 6
by percutaneous access). All animals underwent myoblast
transplantation without complications. There were noTable 1
Experimental model of MI in pigs: baseline data
Control Surgical Percutaneous p
N 4 6 6 NA
Weight 45.5 (5.5) 53.6 (8.2) 49.5 (5.6) 0.378
Heart rate 70.7 (5.4) 70.8 (10.2) 71.4 (8.5) 0.922
Weight of biopsy NA 6.48 (0.9) 7.61 (1.7) 0.206
No. cells injected (×106) NA 434.60 (108.9) 385 (194.4) 0.625
CD56 (%) NA 94 (6.7) 92.1 (9.7) 0.687
No. of injections 11 (1.1) 11 (1.6) 11 (0.9) 0.899arrhythmias, ST-T changes, or Q waves associated with the
procedure. One animal in the control group and one in the
percutaneous group developed non-sustained ventricular
tachycardia during the follow up period (Fig. 1), both within
24 h after myoblast or media implantation. No episodes of
bradiarrhythmia were detected during follow up and no
pericardial effusions were observed on 2D echocardiogram.
Myoblast cultures yielded an average of 407.55±
115×106 cells (190 to 680×106 cells) with a mean
(±SEM) of 92.4±8.2% of myogenic cells (CD56+) of
which 57±16% were labeled with BrdU. Animals in the 2LVEDV
Percutaneous 45.5 (12.1) 55.9 (7.9) 57.9 (19.8) 0.428
Surgical 47.9 (13.4) 65.4 (20.4) 58.9 (16.7) 0.229
Control 41.8 (15.3) 43.7 (21.6) 64.7 (22.2) 0.045
LVESV
Percutaneous 14.3 (1.5) 29.5 (6.5) 25.9 (12.9) 0.778
Surgical 13.8 (3.1) 21.1 (11.6) 19.3 (4.2) 0.558
Control 13.3 (4.9) 28.6 (4.4) 32.2 (18.4) 0.434
p: comparison between pre-transplant values and 3 months post-transplant.
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-
diastolic volume; LVESV: left ventricular end-systolic volume; LVEDD: left
ventricular end-diastolic diameter; LVESD: left ventricular end-systolic
diameter.
Fig. 2. Echocardiographic assessment of LVEF 3 months after SkM
transplant. Numbers represent percentage of change 3 months after SkM
transplant in comparison with pre-transplant values.
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 myoblast transplanted groups (surgical and percutaneous)
received equivalent doses of cells (Table 1). Pigs were
sacrificed 3 months after transplantation.
3.1. Functional assessment
Baseline data for ventricular function were not signifi-
cantly different between groups (Table 2). An akinetic orFig. 3. Myoblast detection in heart sections of animals transplanted with autologous
method. Cm: cardiomyocytes; Myo: skeletal myoblast; F: fibrosis; V: blood vesse
and inflammatory cells (arrows) are observed (scale bar=50 μm). C,D, Immunoh
3 month after surgical and percutaneous transplant (scale bar=50 μm). E, Immuno
Alignment of skeletal myotubes (arrows) (scale bar=100 μm).dyskinetic area either in the lateral or posterolateral wall of
the left ventricle was detected by echocardiography in every
pig. There were no statistically significant differences in the
functional analysis in the control animals regardless of
whether percutaneous or surgical injection of control media
was performed, so both groups were pooled together for
comparison with myoblast transplanted animals. After
myocardial infarction, there was a significant reduction
(p<0.05) in the LVEF that was equivalent in the three groups
(Table 2). Animals receiving myoblasts showed a statisti-
cally significant increase in the LVEF in comparison with
controls, 3 months after transplantation (p<0.05) (Fig. 2),
with no differences between animals receiving myoblasts by
percutaneous or surgical injection (Fig. 2). Although there
were differences between myoblasts treated animals and
controls in the parameters of ventricular remodeling, they did
not reach statistical significance (Table 2).
3.2. SkM engraftment and differentiation
Myoblasts were detected in 11 of 12 animals transplanted
by morphology, BrdU staining and MY-32 labeling (Fig. 3).
To determine the fate of transplanted cells, we performed
double immunohistochemistry against BrdU and specificskeletal myoblast at 3 months after transplantation. A,B, Gallego's trichrome
ls. At higher magnification (insert, scale bar=10 μm) myoblast (arrowhead)
istochemistry against BrdU labeled cells. BrdU positive cells were detected
histochemistry against myosin heavy chain (MY-32) (scale bar=50 μm). F,
 at U
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Fig. 4. SkM transplant is associated with increased vasculogenesis. A, Immunohistochemistry with antibodies against smooth muscle actin (pink) and BrdU
(brown): double positive cells in blood vessels of animals treated with myoblast (scale bar=50 μm). Erythrocytes are observed inside the vessel (arrow). B,
Immunohistochemistry with antibodies against BS-I lectin (endothelial cells) (pink) and BrdU (brown) (scale bar=100 μm). C,D,E, Representative infarct
area stained with antibodies against smooth muscle actin in sections of control (C) surgical (D) and percutaneous (E) treated pigs. F, Area occupied by
smooth muscle coated blood vessels in infarct area (μm2/100.000 μm2). Data are mean±SD, *p<0.05 between SkM treated animals and controls (scale
bar=100 μm).
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 cell markers for cardiac and smooth muscle as well as
endothelial markers. None of the BrdU labeled cells were
stained with markers of cardiomyocytes (not shown).
However, a significant number of BrdU positive cells co-
localized with antibodies against smooth muscle actin (Fig.Fig. 5. Transplantation of SkM is associated with decreased fibrosis in IA and NIA.
staining) in infarct area (A,C) and peri-infarct area (B,D) of animals treated with SkM
pigs. Data are mean±SD, *p<0.05 between SkM treated animals and controls.4). These cells accumulate in areas with an increased number
of blood vessels coated with smooth muscle, suggesting that
some cells within the injected population had the capacity to
differentiate into smooth muscle and contribute to the
formation of new blood vessels (Fig. 4). The presence ofFibrosis (A,B) and collagen Type I/III ratio (C,D) (assessed by picrosirius red
and controls. There was statistically significant less fibrosis in SkM treated
on M
ay 30, 2012
Fig. 6. Representative picrosirius red-stained sections of infarct area (A,B,C) and non-infarct area (D,E,F) show decreased fibrosis in SkM treated pigs (B,C,E,F)
in comparison with control animals (A,D). Collagen stains red and cardiac muscle stains yellow. Scale bar=50 μm.
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 endothelial cells (BS-I lectin+) surrounded with BrdU
positive cells, as well as the presence of erythrocytes inside
the vessels suggests the functionality of the blood vessels.
3.3. SkM induced vasculogenesis
To address potential mechanisms involved in the
beneficial effect of SkM transplant, we analyzed the
presence of vasculogenesis in animals receiving SkM in
comparison with the control group. Arteriolar density was
analyzed by measuring the number of smooth muscle actin
positive vessels in the infarct area of each group of animalsFig. 7. Representative picrosirius red staining of infarct area (A,B,C) and non-infarc
in SkM treated pigs (B,C,E,F) versus control animals (A,D). Collagen type I stains
well as in collagen type I. Scale bar=50 μm.as well as the area occupied by smooth muscle coated blood
vessels. As shown in Fig. 4, the area of SM-actin positive
blood vessels was significantly higher in animals trans-
planted with myoblasts than in the control group (p<0.01),
which suggests an increase in vasculogenesis. No differences
were observed between the two groups of animals receiving
SkM.
3.4. Fibrosis and matrix remodeling
We analyzed the degree of fibrosis in the infarct (IA) and
non-infarct area (NIA) of both control and myoblast treatedt area (D,E,F) under polarized light shows a decreased collagen type I/III ratio
red and collagen type III stains yellow. Note the decrease in total collagen as
avarra on M
ay 30, 2012
Fig. 8. Correlation between CVF and left ventricular function (LVEF) of the
animals (r=−0.861; p=0.003) (y=117.62–1.25x).
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 animals. Quantitative analysis of hearts from animals
receiving SkM demonstrated significantly reduced fibrosis
in the infarct area in comparison with control animals, while
no significant differences were observed in the amount of
fibrosis between cell treated groups. The CVF was 45.9±
4.3% in the control group and 30.9±3.4% and 32.3±9.2% in
animals receiving SkM by surgical or percutaneous delivery
respectively (p<0.05) (Figs. 5 and 6).
It has been demonstrated that dilated cardiomyopathy and
development of CHF are associated with an increase in the
ratio of collagen type I/III [23], so we analyzed the effect of
SkM transplant on the type of collagen in the IA.
Transplantation of SkM was not only associated with
reduced fibrosis but also with a decrease in collagen I/III
ratio in animals treated with SkM (percutaneous injection
0.42±0.13, surgical injection 0.40±0.04) in comparison
with control animals (0.71±0.11), which indicates that type I
collagen deposition was preferentially reduced by transplan-
tation of SkM (Figs. 5 and 7).
Similarly, there was a reduction in the total amount of
fibrosis as well as in the collagen I/III ratio in the NIA of
animals treated with SkM in comparison with controls. As
expected, the degree of fibrosis in the NIA was massively
reduced in comparison with the IA (Figs. 5–7).
Finally, when we analyzed the relation between LVEF
and degree of fibrosis, we observed a negative correlation
between the total area occupied with collagen (CVF) and
LVEF (r=−0.861; p=0.003) (Fig. 8).
4. Discussion
Although previous studies have already established the
potential of SkM to engraft and improve cardiac function in
animal models of MI as well as in patients, most studies have
used a direct intramyocardial injection of cells [3,6,24] and
only one report including a small number of patients has
used percutaneous endomyocardial [11,25] administration.While direct intramyocardial transplantation guarantees that
cells are delivered to the target tissue [26], from a clinical
perspective it has several limitations. Firstly, it requires
major surgery which currently can only be justified if the
patient is undergoing CABG. Second, as administration of
cells is associated with bypass surgery, the benefit of SkM
transplant can only be established by randomized studies. In
this study we demonstrate that echocardiograph guided
endomyocardial transplantation of SkM in a chronic model
of MI results in an improvement in LVEF sustained for at
least 3 months. The fact that both intramyocardial and
endomyocardial administration of SkM were equivalent in
terms of cardiac function, as well as the lack of side effects,
supports the use of percutaneous administration of SkM in
the clinical setting. Although 2D echocardiography provides
a more accurate measurement of ventricle volumes, we
decided to use the Teicholz method instead, due to the fact
that using a 4-cavity apical axis is generally not possible in a
swine model of MI. Further, as our model is based on the
embolization of the circumflex or marginal artery which
induces a lateral or posterolateral MI, the parasternal axis
allows optimal visualization of the infarct in all cases without
significantly altering the geometry of the left ventricle.
The mechanisms by which SkM transplant contributes to
improve cardiac function are largely unknown. Some studies
have suggested that skeletal myoblasts might differentiate
into cardiomyocytes in vitro [14]. It is generally accepted,
though, that myoblasts differentiate into skeletal muscle
fibers which are functionally isolated from host cardiomyo-
cytes [13,27], suggesting that transdifferentiation is very
unlikely to be the mechanism underlying the functional
benefit derived from SkM transplant [2]. Nevertheless, it has
been recently demonstrated in a mouse model, that a minor
population of muscle-derived stem cells can be isolated with
the potential to differentiate in vitro and in vivo into “bona
fide” cardiomyocytes which contribute to improved cardiac
function [28].
The potential of skeletal myoblasts to increase angiogen-
esis in animal models of MI has previously been suggested
[29]. While the release of chemokines such as SDF-1, able to
recruit stem cells with angiogenic potential from the bone
marrow, has been hypothesized in some studies [29], others
suggest that release of angiogenic growth factors such as
VEGF may underlie the angiogenic potential of SkM.
Furthermore, a number of studies have used either direct
delivery of VEGF or VEGF-expressing myoblast in order to
increase angiogenesis in models of MI, with promising
results [16,30,31]. However, a note of caution has been
raised by a study indicating that upregulation of VEGF may
result in deleterious effects including the formation of
vascular tumors in the area of implantation [32]. The results
of our study clearly support the role of SkM in the
stimulation of neovascularization and vasculogenesis —
rather than angiogenesis — as indicated by the increase in
the area occupied by smooth muscle coated vessels.
Interestingly, we found that a number of transplanted cells
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 acquire specific markers of smooth muscle while being
incorporated into the blood vessel wall. Recent studies
indicate that skeletal myoblasts express both VEGFR-1 and
2, and that VEGF regulates proliferation, migration and
differentiation of satellite cells and skeletal myoblast, thus
supporting our findings [33]. However, we cannot exclude
contamination of the implanted population with smooth
muscle cells, despite the high percentage of myoblast in the
cell implant, nor can we rule out fusion between transplanted
myoblast and smooth muscle cells.
Myoblasts also have an effect on the metabolism of
extracellular matrix. Collagens I and III are essential
components of the myocardium, maintaining its structural
and functional integrity. Whereas collagen III forms a
network storing kinetic energy as elastic recoil, collagen I
is a stiff fibrillar protein providing tensile strength.
Because of their different physical properties, the altered
collagen I/III ratio may have an impact on the diastolic and
systolic function of the heart. Significant associations
between increased collagen deposition and elevated
collagen I/III ratio have been observed in autopsy speci-
mens of failing explanted hearts [23,34] and it has also
been suggested that the accumulation of type I collagen
may promote arrhythmias by electrical isolation of adjacent
myocytes.
Development of fibrosis owing to the disruption of the
equilibrium between the synthesis and degradation of
collagen type I and III molecules, which results in an
excessive accumulation of collagen type I and III fibers in
the interstitium and the perivascular regions of the
myocardium, is commonly observed in ischemic or hyper-
tensive failing heart [35]. The observation that the develop-
ment of fibrosis after myocardial infarction was attenuated in
myoblast treated animals along with a decreased collagen
type I/III ratio and the inverse correlation between LVEF and
collagen deposition clearly suggests that SkM transplant is
able to reverse ventricular remodeling, thus contributing to
improved cardiac function. The fact that increased collagen
type I synthesis has been observed in patients with
hypertensive heart disease and heart failure [36] suggests
that the decrease in collagen type I/III ratio in SkM treated
animals could be due to a reduced synthesis of type I
collagen, as has been described for patients with heart failure
treated with β-receptor blockers [37], angiotensin II receptor
antagonists [38] or even resynchronization therapy [39]. We
cannot rule out the possibility that neovascularization in
infarcted myocardium may contribute to decreased fibrosis
by reducing the ischemic area. Similar findings were
observed in rats where MSC transplantation decreased
collagen gene expression, and this effect was more
discernible for type I collagen [40].
Although our study was not specifically designed to
analyze the potential of SkM transplant to induce arrhyth-
mias, the use of implantable loop recorders allowed us to
determine the spontaneous rate of ventricular arrhythmias
during follow up. The two episodes of spontaneousventricular tachycardia were detected in the early period
after transplant, a finding which is consistent with recent
studies [41]. It is possible that SkM transplant may increase
the susceptibility to arrhythmia, as has been recently
suggested using Programmed Electric Stimulation [42].
However, time from infarct to transplantation as well as
baseline arrhythmia susceptibility in patients with chronic
scar tissue may also increase the incidence of arrhythmias,
regardless of cell implant.
We may conclude that 1) transplantation of SkM in a large
animal model of chronic MI is associated with improvement
in cardiac function; 2) importantly, percutaneous echocar-
diograph-guided endomyocardial delivery provides equal
benefit in terms of cardiac function to direct intramyocardial
injection; 3) increased neovascularization and vasculogen-
esis and decreased fibrosis provide some of the mechanisms
involved in the improvement associated with SkM transplant
in chronic MI.
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